CA2385402A1 - Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence - Google Patents

Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence Download PDF

Info

Publication number
CA2385402A1
CA2385402A1 CA002385402A CA2385402A CA2385402A1 CA 2385402 A1 CA2385402 A1 CA 2385402A1 CA 002385402 A CA002385402 A CA 002385402A CA 2385402 A CA2385402 A CA 2385402A CA 2385402 A1 CA2385402 A1 CA 2385402A1
Authority
CA
Canada
Prior art keywords
treatment
sapogenin
dementia
beta
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002385402A
Other languages
English (en)
Other versions
CA2385402C (fr
Inventor
Paul Barraclough
Jim Hanson
Phil Gunning
Daryl Rees
Zongqin Xia
Yaer Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytopharm Ltd
Original Assignee
Phytopharm Plc
Paul Barraclough
Jim Hanson
Phil Gunning
Daryl Rees
Zongqin Xia
Yaer Hu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Plc, Paul Barraclough, Jim Hanson, Phil Gunning, Daryl Rees, Zongqin Xia, Yaer Hu filed Critical Phytopharm Plc
Priority to CA002640998A priority Critical patent/CA2640998A1/fr
Publication of CA2385402A1 publication Critical patent/CA2385402A1/fr
Application granted granted Critical
Publication of CA2385402C publication Critical patent/CA2385402C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
CA002385402A 1999-09-29 2000-09-29 Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence Expired - Fee Related CA2385402C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002640998A CA2640998A1 (fr) 1999-09-29 2000-09-29 Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9923076.5 1999-09-29
GBGB9923076.5A GB9923076D0 (en) 1999-09-29 1999-09-29 Sapogenin derivatives and their use
PCT/GB2000/003737 WO2001023406A1 (fr) 1999-09-29 2000-09-29 Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002640998A Division CA2640998A1 (fr) 1999-09-29 2000-09-29 Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence

Publications (2)

Publication Number Publication Date
CA2385402A1 true CA2385402A1 (fr) 2001-04-05
CA2385402C CA2385402C (fr) 2009-01-13

Family

ID=10861837

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002385402A Expired - Fee Related CA2385402C (fr) 1999-09-29 2000-09-29 Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence
CA002640998A Abandoned CA2640998A1 (fr) 1999-09-29 2000-09-29 Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002640998A Abandoned CA2640998A1 (fr) 1999-09-29 2000-09-29 Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence

Country Status (27)

Country Link
US (2) US7138427B2 (fr)
EP (2) EP1224205B1 (fr)
JP (1) JP2003510332A (fr)
KR (1) KR100771491B1 (fr)
CN (2) CN100445295C (fr)
AT (1) ATE325808T1 (fr)
AU (1) AU778294C (fr)
BR (1) BR0014381A (fr)
CA (2) CA2385402C (fr)
CY (1) CY1105225T1 (fr)
CZ (1) CZ300150B6 (fr)
DE (1) DE60027913T2 (fr)
DK (1) DK1224205T3 (fr)
ES (1) ES2260055T3 (fr)
GB (1) GB9923076D0 (fr)
HK (1) HK1045525B (fr)
HR (2) HRP20020255A2 (fr)
IL (2) IL148920A0 (fr)
MX (1) MXPA02003305A (fr)
NO (1) NO324959B1 (fr)
NZ (1) NZ518596A (fr)
PT (1) PT1224205E (fr)
RU (1) RU2325396C2 (fr)
TR (1) TR200200821T2 (fr)
UA (1) UA82978C2 (fr)
WO (1) WO2001023406A1 (fr)
ZA (1) ZA200202382B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
NZ547897A (en) * 2002-03-27 2008-02-29 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
CA2477787C (fr) * 2002-03-27 2011-12-20 Phytopharm Plc Methodes therapeutiques et utilisations des sapogenines et de leurs derives
PT1490071E (pt) * 2002-03-27 2009-05-25 Phytopharm Plc Métodos terapêuticos e utilizações de sapogeninas e seus derivados
PL210114B1 (pl) * 2002-10-28 2011-12-30 Phytopharm Plc Sposób stereospecyficznego wytwarzania 3β-hydroksy-5β-H-steroidowych sapogenin
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
KR20110115589A (ko) 2009-01-24 2011-10-21 파이토팜 피엘씨 신경영양인자가 매개된 장애의 치료
CN101768202B (zh) * 2009-02-18 2013-10-30 沈阳药科大学 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途
WO2012010896A1 (fr) 2010-07-20 2012-01-26 Phytopharm Plc Traitement de troubles induits par la l-dopa, un agoniste de dopamine et/ou un activateur de dopamine
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
US11319338B2 (en) 2012-04-03 2022-05-03 Goldporp Pharma Limited Timosaponin compounds
CN102924559B (zh) * 2012-11-16 2015-10-28 沈阳药科大学 菝葜皂苷元衍生物及其制备和应用
GB201305708D0 (en) * 2013-03-28 2013-05-15 Clasado Inc Novel use
CN103232520A (zh) * 2013-05-13 2013-08-07 中国药科大学 一种螺甾类化合物、其制备方法及医药用途
CN104513289B (zh) * 2015-01-27 2017-12-22 华东理工大学 知母皂苷元结构修饰的衍生物、其药物组合物及其应用
JP6791977B2 (ja) * 2015-10-29 2020-11-25 エミオン インコーポレイテッドＥｍｍｙｏｎ， Ｉｎｃ． 骨格筋の肥大剤としてのフロスタン−３オール誘導体
CN106977581B (zh) * 2017-04-17 2021-01-01 华东理工大学 知母皂苷元结构修饰的衍生物的应用以及药物组合物

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852847A (en) 1958-03-04 1960-11-02 British Drug Houses Ltd Improvements in or relating to 6-methyl steroid compounds
US3575810A (en) 1967-07-19 1971-04-20 Takashi Matsushima Method for removal of side chain of sapogenins
BE794362A (fr) 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3929769A (en) 1972-05-19 1975-12-30 Ciba Geigy Corp Process for the manufacture of steroid epoxides
CA985172A (en) 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
DE2416978A1 (de) 1974-04-08 1975-10-09 Degussa Arzneimittel mit dem hauptsapogenin der helleborus-arten als wirkstoff
LU81256A1 (fr) 1979-05-15 1980-12-16 Oreal Composition cosmetique capillaire notamment pour le lavage et/ou le demelage des cheveux,a base d'un extrait de plantes contenant des saponosides
IT1144136B (it) 1980-03-05 1986-10-29 Zenyaku Kogyo Kk Glucosidi di condurango agenti antitumorali che li comprendono e procedimento per la loro preparazione
GB2097672A (en) 1981-05-01 1982-11-10 Pattni Ramesh Damji Devji Process for extraction of crude sapogenins from Agave Leaves
JPS5855500A (ja) 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk １６−デヒドロプレグネノロンの製造法
US4602003A (en) 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4562250A (en) 1982-09-13 1985-12-31 Regents Of The University Of Minnesota Steroidal glycosides produced by Yucca tissue culture
US4546097A (en) 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPS62234025A (ja) 1986-04-03 1987-10-14 Asahi Chem Ind Co Ltd 老人性痴呆者用食品
US5017562A (en) 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
DE3838716A1 (de) 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie
JPH02188528A (ja) 1989-01-13 1990-07-24 Tsurataka Tashiro 痴呆症治療薬
CA2073855C (fr) 1990-01-18 2007-04-24 Bill Elliot Cham Glycoalcaloides pour la regulation de l'autophagie cellulaire
SE9100342D0 (sv) 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
US5252729A (en) 1991-10-23 1993-10-12 Schering Corporation Extraction of compounds from plant materials using supercritical fluids
US5244887A (en) 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
CA2139104A1 (fr) 1992-06-26 1994-01-06 Michael P. Deninno Glycosides steroides pour le traitement de l'hypercholesterolemie
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
WO1994018994A1 (fr) 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Composition therapeutique a base d'herbes
CN1052636C (zh) 1993-03-29 2000-05-24 中国科学院沈阳应用生态研究所 文冠果子的醇提取物在制备治疗智力低下的药物中的应用
CN1092992A (zh) 1993-03-29 1994-10-05 中国科学院沈阳应用生态研究所 提高脑功能的药物及其制备方法
JPH06305952A (ja) 1993-04-27 1994-11-01 Sumitomo Pharmaceut Co Ltd スレオ−３−（３，４−ジヒドロキシフェニル）セリン経鼻投与製剤
EP0696292A1 (fr) 1993-04-28 1996-02-14 Pfizer Inc. Monohydrate cristallin glycosidique de spirostanyle
CN1033754C (zh) * 1993-05-31 1997-01-08 上海第二医科大学 知母皂甙元作为制备β肾上腺素和M胆碱受体双向调节药的用途及其制法
CN1102186A (zh) 1993-10-29 1995-05-03 沈阳医学院 中药薤白新成分的鉴定及用途
US5589182A (en) 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
US5698526A (en) 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
EP0737202A1 (fr) 1993-12-28 1996-10-16 Pfizer Inc. Agents hypocholesterolemiques
IL109614A (en) 1994-05-10 1998-06-15 Yissum Res Dev Co Comestible products containing saponins
US5563131A (en) 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
KR970705574A (ko) 1994-08-30 1997-10-09 스피겔 알렌 제이 스피로스타닐 글리코시드 결정(spirostanyl glycosidal crystals)
CA2200436A1 (fr) 1994-09-20 1996-04-04 Pfizer Inc. Combinaison d'un inhibiteur d'absorption du cholesterole et d'un inhibiteur de synthese du cholesterol
WO1996038466A1 (fr) 1995-05-29 1996-12-05 Pfizer Inc. Glycosides steroidiques
US6143738A (en) 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5795885A (en) 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5763430A (en) 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5840936A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
JPH09100295A (ja) 1995-06-13 1997-04-15 Toray Ind Inc 新規トリテルペノイドサポニン類およびそれを有効成分とする神経突起伸展作用を有する治療剤
CU22860A1 (es) 1995-10-12 2003-05-26 Univ La Habana Espirostanonas con funciones oxigenadas en el anillo a. como reguladores del crecimiento vegetal y su procedimiento de obtención
WO1997013766A1 (fr) 1995-10-13 1997-04-17 Banyu Pharmaceutical Co., Ltd. Derives heteroaromatiques substitues
FR2743561B1 (fr) 1996-01-15 1998-02-20 Fournier Sca Lab Derives de steroides, procede de preparation et utilisation en therapeutique
KR0169536B1 (ko) 1996-02-27 1999-01-15 손경식 신규한 인삼 사포닌, 그의 제조방법 및 이를 유효성분으로 하는 항종양제
US5726179A (en) 1996-04-01 1998-03-10 The University Of Toledo Muscarinic agonists
ATE281170T1 (de) 1996-05-09 2004-11-15 Amrad Operations Pty Ltd Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen
CA2632790A1 (fr) 1996-07-22 1998-01-29 Renovo Limited Utilisation de modulateurs de l'activite de steroides sexuels pour le traitement de plaies et d'etats pathologiques de type "fibreux"
US5804239A (en) 1996-07-26 1998-09-08 Nouveau Technologies, Inc. Method and composition for food flavoring
AU7580098A (en) 1997-05-15 1998-12-08 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
AU7980098A (en) 1997-06-20 1999-01-04 Elena Y. Enioutina Method to enhance innate immunity defense mechanisms by treatment with plan t-derived alkaloids
WO1999009837A1 (fr) 1997-08-28 1999-03-04 Cv Technologies Inc. Standardisation chimique et pharmacologique des extraits de plantes medicinales
JP3906948B2 (ja) * 1997-09-13 2007-04-18 本田技研工業株式会社 電動式変速装置の変速制御装置
CN1131237C (zh) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
CA2217088A1 (fr) 1997-09-30 1999-03-30 Universite De Sherbrooke Nouveaux derives de mandevilla velutina comme agents de blocage en continu des canaux ca2+ de type r, methode de production et utilisations
JP3873097B2 (ja) 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
AU3158199A (en) * 1998-03-26 1999-10-18 Phytopharm Plc. Smilagenin and anzurogenin-d and their use
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9905275D0 (en) 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
KR100292406B1 (ko) 1998-06-11 2001-07-12 윤종용 감광성중합체,용해억제제및이들을포함하는화학증폭형포토레지스트조성물
GB2347676A (en) 1999-03-08 2000-09-13 Phytopharm Plc Screening method
GB9923078D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPP968699A0 (en) 1999-04-09 1999-05-06 Cura Nominees Pty Ltd Therapeutic compositions and method for their preparation
US6544566B1 (en) 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
BR0001794A (pt) 2000-05-15 2001-12-26 Laboratorios Biosintetica Ltda Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares)
US20050130948A1 (en) 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives

Also Published As

Publication number Publication date
US20030004147A1 (en) 2003-01-02
CN1377368A (zh) 2002-10-30
US20060276415A1 (en) 2006-12-07
CN101411712A (zh) 2009-04-22
DE60027913T2 (de) 2007-01-11
EP1224205A1 (fr) 2002-07-24
CA2385402C (fr) 2009-01-13
NO324959B1 (no) 2008-01-14
PT1224205E (pt) 2006-08-31
CZ300150B6 (cs) 2009-02-25
EP1724279A2 (fr) 2006-11-22
UA82978C2 (ru) 2008-06-10
DK1224205T3 (da) 2006-06-12
TR200200821T2 (tr) 2002-06-21
ZA200202382B (en) 2003-09-23
US7507720B2 (en) 2009-03-24
DE60027913D1 (de) 2006-06-14
IL180972A0 (en) 2007-07-04
BR0014381A (pt) 2002-06-25
IL148920A0 (en) 2002-09-12
ES2260055T3 (es) 2006-11-01
GB9923076D0 (en) 1999-12-01
MXPA02003305A (es) 2002-10-04
NZ518596A (en) 2004-07-30
NO20021541L (no) 2002-05-28
HRP20020255A2 (en) 2003-08-31
NO20021541D0 (no) 2002-03-27
ATE325808T1 (de) 2006-06-15
AU7537500A (en) 2001-04-30
RU2325396C2 (ru) 2008-05-27
US7138427B2 (en) 2006-11-21
CN100445295C (zh) 2008-12-24
HK1045525A1 (en) 2002-11-29
US20060100184A9 (en) 2006-05-11
CY1105225T1 (el) 2010-03-03
PL357370A1 (en) 2004-07-26
HRP20080467A2 (en) 2008-11-30
AU778294C (en) 2005-08-04
WO2001023406A1 (fr) 2001-04-05
HK1045525B (zh) 2006-08-04
EP1224205B1 (fr) 2006-05-10
CA2640998A1 (fr) 2001-04-05
KR20020092914A (ko) 2002-12-12
KR100771491B1 (ko) 2007-10-30
AU778294B2 (en) 2004-11-25
JP2003510332A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
CA2385402A1 (fr) Derives de 5-beta-sapogenine et de pseudosapogenine et leurs utilisations dans le traitement de la demence
World Health Organization The health of indigenous peoples
WO1999048482A3 (fr) Smilagenine et anzurogenine d et leur utilisation
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2386201A (en) Substituted sapogenins and their use
AU2002359161A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002310256A1 (en) Ppp2cs as modifiers of the p53 pathway and methods of use
CA2387873A1 (fr) Derives nordihydroguaiartiques destines a une utilisation dans le traitement de tumeurs
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU7538700A (en) 5-hydroxysapogenin derivatives with anti-dementia activity
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
AU2003278664A1 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
AU2002306600A1 (en) Sperm protein 17 for the diagnosis and treatment of cancer
AU2001266790A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2003248893A1 (en) Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias
AU2001294999A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
Gábor Effect of capsaicin on the function of isolated heart under physiological and pathological conditions. Possible role of neural endothelin
Strawson Précis of Mental Reality
Opp " Those who are silent have something to say"; participatory rural appraisal and the discourses of development.
Rahman Limiting the role of State
AUPQ475499A0 (en) Phosphoglycerate kinase in the treatment of disease

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed